Contrast-enhanced MR imaging of the liver

Applied Radiology

Volumn 29, Issue 4, 2000, Pages 29-34

  Chauhan, Ajay ^a   Sahani, Dushyant V ^a   Saini, Sanjay ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0005047985     PISSN: 01609963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0160-9963(00)80194-6     Document Type: Article

References (21)

1. Malt R: Surgery for hepatic neoplasms. N Engl J Med 313:1591-1596, 1985.
2. Sugarbaker P: Surgical decision making for large bowel cancer metastatic to the liver. Radiology 174:621-626, 1990.
3. Karhunen P: Benign hepatic tumors and tumor-like conditions in men. J Clin Pathol 39:183-187, 1986.
4. Beers BV, Gallez B, Pringot J: Contrast-enhanced MR imaging of the liver. Radiology 203:297-306, 1997.
5. Hahn P, Saini S: Liver-specific MR imaging contrast agents. Radiol Clin North Am 36:287-297, 1998.
6. Mitchell D: Hepatobiliary contrast material: A magic bullet for sensitivity and specificity? Radiology 188:21-22, 1993.
7. Nelson K, Gifford L, Lauber-Huber C, et al: Clinical safety of Gadopentetate dimeglumine. Radiology 196:439-443, 1995.
8. Van Beers B, Demeure R, Pringot J, et al: Dynamic spin-echo imaging with Gd-DTPA: Value in the differentiation of hepatic tumors. AJR 154:515-519, 1990.
9. Tang Y, Yamashita Y, Arakawa A, et al: Detection of hepatocellular carcinoma arising in cirrhotic livers: Comparison of gadolinium- and ferumoxides-enhanced MR imaging. AJR 172:1547-1554, 1999.
10. Bernardino M, Young S, Lee J, Weinreb J: Hepatic MR imaging with Mn-DPDP: Safety, image quality, and sensitivity. Radiology 183:53-58, 1992.
11. Murakami T, Baron RL, Peterson MS, et al: Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP). Radiology 200:69-77, 1996.
12. Rofsky N, Weinreb J, Bernardino M, et al: Hepatocellular tumors: Characterization with Mn-DPDP-enhanced MR imaging. Radiology 188:53-59, 1993.
13. Ni Y, Petre C, Lukito G, et al: Effect of manganese dipyridoxal diphosphate on liver magnetic resonance imaging and serum bilirubin in rats with removable billiary obstruction. Acad Radiol 2:300-305, 1995.
14. Ferrucci JT, Stark DD: Iron oxide enhanced imaging of the liver and spleen: Review of first 5 years. AJR 155:943-950, 1990.
15. Vogl T, Hammersting l R, Schwarz W, et al: Superparamagnetic iron oxide-enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions. Radiology 198:881-887, 1996.
16. Hagspiel K, Neidl K, Eichenberger A, et al: Detection of liver metastases: Comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US, and percutaneous US. Radiology 196:471-478, 1995.
17. Ros P, Freeny P, Harms S, et al: Hepatic MR imaging with ferumoxides: A multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 196:481-488, 1995.
18. Seneterre E, Taourel P, Bouvier Y, et al: Detection of hepatic metastases: Ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography. Radiology 200:785-792, 1996.
19. Ward J, Naik KS, Guthrie JA, et al: Hepatic lesion detection: Comparison of MR imaging after the administration of superparamagnetic iron oxide with dual-phase CT by using alternative-free response receiver operating characteristic analysis. Radiology 210:459-466, 1999.
20. Grandin C, Van Beers B, Pauwels S, et al: Ferumoxides and Tc-99m sulfur colloid: Comparison of the tumor-to-liver uptake in focal nodular hyperplasia. J Magn Reson Imaging 7(1):125-129, 1997.
21. Rummeny EJ, Ehrenheim C, Gehl HB, et al: Manganese-DPDP as hepatobiliary contrast agent in MR imaging of liver tumors: Results of clinical phase II trials in Germany including 141 patients. Invest Radiol 27:879-886, 1992.